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TheherpesviridaearealargefamilyofDNAviruseswithlargeandcomplicatedgenomes.Geneticmanipulationandthegeneration
of recombinant viruses have been extremely diﬃcult. However, herpesvirus bacterial artiﬁcial chromosomes (BACs) that were
developed approximately 10 years ago have become useful and powerful genetic tools for generating recombinant viruses to study
the biology and pathogenesis of herpesviruses. For example, BAC-directed deletion mutants are commonly used to determine
the function and essentiality of viral genes. In this paper, we discuss the creation of herpesvirus BACs, functional analyses of
herpesvirus mutants, and future applications for studies of herpesviruses. We describe commonly used methods to create and
mutate herpesvirus BACs (such as site-directed mutagenesis and transposon mutagenesis). We also evaluate the potential future
uses of viral BACs, including vaccine development and gene therapy.
1.Introduction
Human herpesviruses are a leading cause of human viral
disease, second only to inﬂuenza and cold viruses [1].
Herpesvirusescontaina largedouble-stranded DNA genome
that ranges in size from 125 to 240kilobase pairs. Their
genomes are tightly packed in virions in a linear form but
become circularized once they enter the nucleus (where they
replicate) [2]. This circularization becomes important for
herpesvirus BAC construction, which we will discuss in this
paper. All herpesviruses undergo a latent infection following
primary infection. During latency, the virus remains dor-
mant and is able to evade the host immune system. Under
several circumstances, lytic replication can be reactivated in
latent viruses, thereby causing various types of disease. This
characteristic makes herpesvirus infections especially hard to
treat.
There are eight human herpesviruses: herpes simplex
virus 1 (HSV-1 or HHV-1), herpes simplex virus 2 (HSV-2
or HHV-2), varicella-zoster virus (VZV or HHV-3), Epstein-
Barr virus (EBV or HHV-4), human cytomegalovirus
(HCMV or HHV-5), human herpesvirus 6 (HHV-6), human
herpesvirus 7 (HHV-7), and Kaposi’s sarcoma-associated
herpesvirus (KSHV or HHV-8) [2]. HSV-1 and 2 are the
causalagentsoforalandgenitalherpes,respectively[3].VZV
is the causal agent of chickenpox and shingles [4]. HCMV
is a major cause of infectious morbidity and mortality in
immunocompromised individuals and developing fetuses,
and HCMV-caused disease is called cytomegalovirus inclu-
sion disease (CID) [5]. HHV-6 is associated with roseola
[6]. EBV is associated with a number diseases, most notably
infectious mononucleosis (colloquially known as mono or
kissing disease) and Burkitt’s lymphoma [7]. As the name
implies, KSHV is associated with Kaposi’s sarcoma [8], but
KSHV can also cause B-cell lymphoma.
Ever since the creation of the ﬁrst herpesvirus bac-
terial artiﬁcial chromosome (BAC) mutant (for murine
cytomegalovirus, MCMV) over a decade ago, mutagenesis2 Journal of Biomedicine and Biotechnology
using BAC technology has been proven to be an invaluable
tool for studying herpesvirus pathogenesis [9–13]. BACs
are especially useful for studying herpesviruses because the
DNAs of these viruses are too large to be cloned in individual
plasmids or cosmids [13]. Although Yeast Artiﬁcial Chro-
mosomes (YACs) can also be used to carry large genomic
sequences, BACs are more suitable for viral studies because
BACs are more stable than YACs and are less prone to
undesired genomic rearrangements and contamination with
yeast DNA [14, 15]. BACs are especially useful for many
herpesviruses because of their especially slow replication
rate and the relative ease and accuracy of producing BAC
mutants.Additionally,viralBACsinE.colicanbemorestable
than traditional or natural viral mutants. In particular, viral
BAC-containing E. coli strains can be stored at −80◦C, and
new viruses can quickly be produced from BAC DNAs. In
contrast, clinical isolates can become attenuated by repeated
culture passage in vitro. However, the stability of viral BACs
needs to be periodically checked, especially because viruses
will be subject to diﬀerent selective pressures in bacterial
and mammalian cells, and viral BACs may acquire undesired
mutants after replicating in E. coli [9, 10]. For example,
repetitive sequences in the viral DNA have been shown
cause unwanted phenotypic changes when viral BACs are
replicated in E. coli [16]. Researchers also need to be able
to produce a variety of diﬀerent type of BAC mutants (such
as stop-codon mutants or premature-frameshift mutants)
in order to ensure that a mutation is due to a change in
the functionality of a given gene (as opposed to disrupt-
ing cis-regulatory elements or altering the positioning of
enhancers).
Viral BACs are created by inserting a BAC vector
sequence into a viral genome. Methods for the construction
of viral BACs are outlined in the second section of this paper.
There are two commonly used methods to mutagenize BAC
DNA: random transposon and site-directed mutagenesis.
Site-directed mutagenesis utilizes homologous recombina-
tion to create speciﬁc mutations in viral genes. In contrast,
transposon mutagenesis creates a large diversity of BAC
mutants, but mutagenesis is random, and sequencing or
PCR is required to determine the mutation site. A detailed
description of the methods for the mutagenesis of viral BACs
is provided in the third section of this paper.
V i r a lB A C sh a v eb e e nc r e a t e df o re v e r yh u m a nh e r -
pesvirus except HHV-7 and several animal herpesviruses
that are frequently used as animal models for studying
viralpathogenesis(includingmurinecytomegalovirus,pseu-
dorabies virus, and herpesvirus saimiri). We will review
some speciﬁc studies of BAC creation and mutagens for
both human and nonhuman herpesviruses in the fourth
section of this paper. We will also discuss global mutagenesis
studies in the ﬁfth section of this paper. A list of human
h e r p e s v i r u sB A C si sp r o v i d e di nTable 1, and a list of animal
herpesviruses is provided in Table 2. There are also a number
ofotherusefulapplicationsforBACmutants(suchasvaccine
development and gene therapy), and we will review potential
future uses of viral BAC mutants in the concluding section of
this paper.
2. Methods for BAC Construction
2.1. Features of the BAC Vector. The crucial feature that
deﬁnes a viral BAC is the presence of a BAC vector within the
viral genome [15]. A typical BAC vector is about 10 kilobase
pairs long and must have an origin of replication (e.g., oriS),
genes necessary for BAC replication (such as repE), and
genes to control the rate of replication in order to limit the
copy number to one or two BACs per bacterial cell (such
as parA and parB). An antibiotic resistance marker (such as
chloramphenicol) must also be contained within the BAC
vectorinordertoselectonlythebacterialcoloniescontaining
the BAC herpesvirus of interest. The BAC vector must also
be ﬂanked by 500–1000 base pairs that are homologous to
the target sequence where the BAC vector will be inserted. In
order to isolate BAC-containing recombinant virus, a BAC
vector should also carry a selectable marker (such as GFP,
beta-galactosidase, antibiotic resistance genes, or metabolic
genes). In addition, two loxP sites are often included at both
ends of the BAC sequence so that the BAC vector can be
excised out when recombinant viruses are generated (see
discussion below).
2.2. Direct Insertion of BAC Vector into Viral Genome via
Homologous Recombination. One commonly used method
of constructing herpesvirus BACs involves inserting a BAC
vector into a speciﬁc site of the viral genome via homologous
recombination [12, 17, 21, 24–26, 31, 32]. For this process,
the BAC vector with ﬂanked viral genomic sequences is
linearized using restriction enzymes and cotransfected with
puriﬁed viral genomic DNA into viral permissive cells. Some
herpesviruses, such as HCMV and MCMV, contain large
genomes and limited capsid capacity. Insertion of a 10-Kb
BAC vector will cause severe growth defects in these viruses
[50]. Therefore, replacement of a long nonessential region of
the viral genome is required for viral BAC construction. If
necessary, the original viral sequence can be reinserted once
the BAC [51]o rm o v e dt oad i ﬀerent location in the viral
genome [23]. Homologous recombination takes place in the
cells, and a recombinant virus carrying a BAC vector will be
produced.Viralplaquesarepuriﬁedbaseduponthepresence
of a trait deﬁned by a selectable marker. For example,
recombinant virus infection will show green ﬂuorescent
plaques if the BAC vector contains a GFP expression cassette
as a selectable marker. The BAC vector-containing viral DNA
is isolated from infected cells and again inserted into a RecA
E. coli strain, such as DH10B, via electroporation. Although
herpesvirus DNA is large and diﬃcult to transform into E.
coli, the fact that herpesvirus genome circularizes during
replication makes this step feasible. Bacterial cells containing
viral BACs can be selected based upon the antibiotic
marker present in the BAC vector (e.g., chloramphenicol, as
described above). If a viral BAC can be stably maintained
and replicated in E. coli, drug-resistant colonies will be
obtained. Site-directed mutagenesis can also occur during
this step (see the following section). The viral BAC DNA is
puriﬁed from E. coli and restriction enzyme digestion and,
sometimes, partial sequencing analyses are performed to
conﬁrm that there have been no major mutations (deletions)Journal of Biomedicine and Biotechnology 3
Table 1: BAC-based human herpesvirus studies.
Virus Global deletion? Representative studies
Herpes Simplex Virus-1 (HSV-1) No
Horsburgh et al. 1999 [17]
Saeki et al. 1998 [18]
Stavropoulos and Strathdee 1998 [19]
Herpes Simplex Virus-2 (HSV-2) No Meseda et al. 2004 [20]
Varicella Zoster Virus (VZV) Yes
Nagaike et al. 2004 [21]
Zhang et al. 2007 [22]
Wussow et al. 2009 [23]
Epstein-Barr Virus (EBV) No Delecluse et al. 1998 [24]
Cytomegalovirus (CMV) Yes
Borst et al. 1999 [25]
Marchini et al. 2001 [26]
Hahn et al. 2002 [27]
Murphy et al. 2003 [28]
Sinzger et al., 2008 [29]
Dulal et al. 2009 [30]
Human Herpesvirus 6 (HHV-6) No Borenstein and Frenkel 2009 [31]
Human Herpesvirus 7 (HHV-7) No BAC NA
Kaposi’s Sarcoma-Associated Herpesvirus (KSHV) No Delecluse et al. 2001 [32]
Zhou et al. 2002 [33]
In most cases, “representative studies” represent the ﬁrst BAC produced for each human herpesvirus. Hahn et al. 2002, Marchini et al. 2001, and Murphy et
al. 2002 correspond to creation of BACs for other alternative strains of HCMV. Zhang et al. 2007 and Dulal et al. 2009 refer to the ﬁrst BACs with a luciferase
reporter genes.
Table 2: Selected BAC-based animal herpesvirus studies.
Virus Global deletion? Representative studies
Bovine Herpesvirus Type 1 (BHV-1) Yes Mahony et al. 2002 [34]
Robinson et al. 2008 [35]
Equine Herpesvirus Type 1 (EHV-1) No Rudolph et al. 2002 [36]
Feline Herpesvirus Type 1 (FHV-1) No Costes et al. 2006 [37]
Guinea Pig Cytomegalovirus (GPCMV) No McGregor and Schleiss 2001 [38]
Herpesvirus Saimiri (HVS) No White et al. 2003 [39]
Koi Herpesvirus (KHV) No Costes et al. 2008 [40]
Marek’s Disease Virus (MDV) No Schumacher et al. 2000 [41]
Murine Cytomegalovirus (mCMV) Yes
Messerle et al. 1997 [12]
Brune et al. 1999 [42]
Bubeck et al. 2004 [43]
Murine Gammaherpesvirus 68 (MHV-68) Yes Adler et al. 2000 [44]
Song et al. 2005 [45]
Pseudorabies Virus (PrV) No Smith and Enquist 1999 [46]
Rhesus Cytomegalovirus (rhCMV) No Chang and Barry 2003 [47]
Rhesus Rhadinovirus (RRV) No Estep et al. 2007 [48]
Turkey Herpesvirus (HVT) No Baigent et al. 2006 [49]
In most cases, important BACs represent the ﬁrst BAC produced for a given virus. The work of Brune et al. (1999), Bubeck et al. (2004), Robinson et al.
(2008), and Song et al. (2005) are global mutagenesis studies.
in the BAC DNA [22]. The integrity of the BAC can also be
conﬁrmed via next-generation sequencing, and this practice
may become commonplace in the future. Once the integrity
of the viral BAC is conﬁrmed, large amounts of the BAC
DNA can be produced in bacterial cells before transfection
into mammalian cells. Since the large herpesvirus genome
is diﬃcult to transfect, the ability to produce large amounts
and high quality of viral BAC DNA has been a very
useful development that has signiﬁcantly aided the study
of herpesvirus pathogenesis. The process is outlined in
the context of the production of the HCMV BAC in
Figure 1.4 Journal of Biomedicine and Biotechnology
2.3. Using Overlapping Cosmids to Produce Viral BACs.
Herpesvirus BACs can also be constructed using a set of
overlapping cosmids covering the whole genome of a virus
[18, 19, 22]. This method was necessary for the creation
of the VZV BAC because it is diﬃcult to isolate the full-
length VZV genome and purify recombinant viral plaques
due to the highly cell-associated nature of the virus [21].
For this process, multiple cosmids (usually 3–6) containing
partial herpesvirus genomic sequences are constructed such
that each cosmid will contain an overlapping sequence when
linearized, and this allows the cosmids to recombine into
one large virus genome via homologous recombination in
a eukaryotic cell. Recombinant viruses could be produced
using overlapping cosmids prior to the creation of viral
BACs [54–58]. Insertion of a BAC vector into one of the
genomic cosmids via homologous recombination is the key
step that allows the rapid creation of recombinant viruses
that can be genetically manipulated in E. coli.B A Cv e c t o r s
can also be inserted into a genomic sequence using the
restriction enzyme digestion of viral DNA along with BAC
vector, followed by ligation and the Hirt extraction of the
recombinant virus [31]. After insertion of the BAC vector,
the overlapping cosmids are combined and the resulting
viral BAC DNA is circularized following transfection into
mammalian cells. Plaques containing the BAC vector can be
visualized using a selectable marker, such as GFP. At this
point, the process of viral BAC production is identical to
the method of direct insertion (see above). This process is
outlined in the context of the production of the VZV BAC in
Figure 2.
2.4. BAC Visualization Markers. By adding a number of
features to the viral BAC genome, it is possible to visualize
and quantify viral replication and thereby study viral patho-
genesis. For example, a GFP reporter gene is often inserted
into BAC DNAs in order to visualize in vitro infections in
cell culture [18, 21, 24, 32]. Viral GFP is expressed using
SV40 promoter and polyadenylation signals, and this allows
the GFP gene to be expressed during the appropriate stages
of viral replication [26]. A luciferase reporter can also be
inserted into viral BACs, which insertion is especially useful
forstudyinginvivoinfectionsinorganculturesandinSCID-
hu implants [22, 30, 53, 59]. Luciferase activity correlates
with viral replication, and the luciferease reporter also allows
for multiple measurements within the same culture or host
(which is much more eﬃcient than titration assays, which
would require mice to be sacriﬁced for each measurement).
In addition to aiding in the study of viral pathogenesis, EBV
and HSV viral vectors with luciferase can also be useful for
developing gene therapy treatments [60, 61]( f o rm o r ea b o u t
gene therapy, see the ﬁnal section of this paper). Prior to the
invention of herpesvirus BACs, it was more diﬃcult to utilize
luciferase to study viral replication. For example, one study
utilized a human cell line with a luciferase reporter gene
with an HSV promoter such that the expression of luciferase
correlated with HSV infection [62].
Integrity of visualization markers can be checked peri-
odically using the in vitro infection of human cells in order
to ensure that undesired, accumulated mutations have not
compromised the integrity of the luciferase reporter gene.
If serial dilutions of viral plaques reveal that visualization
markers are consistently present in the vast majority of
plaques, then it should be safe to assume that reporter
gene expression will accurately correlate with viral repli-
cation [22]. Viral BAC integrity can also be periodically
conﬁrmed by isolating DNA and performing restriction
digest analysis as well as the random sequencing of gene
sequences.
Once the viral BAC is created, functional analysis of each
viral gene can be conducted by site-directed mutagenesis of
the viral BAC DNA. The two most commonly used methods
for BAC DNA manipulation are site-directed mutagenesis
and transposon mutagenesis.
3. Methods for BAC Mutagenesis
3.1. Use of E. coli for Site-Directed Mutagenesis via Homolo-
gousRecombination. GeneticallymodiﬁedE.coli(mostcom-
monly, DY380-derived strains) have become a very popular
tool to help create recombinant DNA using homologous
recombination [63, 64]. Wild-type E. coli is ineﬀective
at inducing homologous recombination in foreign DNA
because linear DNA is commonly degraded by RecBCD
exonuclease (exo) .I no r d e rt oc i r c u m v e n tt h i sp r o b l e m ,
DY380-derived strains contain a temperature-sensitive λ
phage containing one gene to temporarily repress RecBCD
(gam), as well as two genes (exo and beta)u t i l i z e df o r
homologous recombination via double-strand break repair
[64]. More speciﬁcally, exonuclease degrades DNA from
the 5  end of double-strand break sites, while Beta binds
to and protects the 3  from further degradation [65, 66].
These overhangs from double-strand breaks allow recom-
bination between viral and plasmid DNA. Because the
λ phage is temperature sensitive (due to the expression
of a temperature-sensitive λ cI-repressor), linear DNA
uptake and recombination can occur within a few minutes
when the cell-culture temperature is increased from 32
to 42◦C[ 64]. This allows the bacterial cells to function
normally when grown at 32◦C, which is necessary for BAC
production
E. coli also requires thousands of homologous base
pairs in order for recombination to occur. Addition of the
modiﬁedtemperature-sensitiveλphageisimportantbecause
t h i sa l l o w sh o m o l o g o u sr e c o m b i n a t i o nt oo c c u rw i t h i na
relatively small region of the homologous sequence, which
is important because BAC mutants are usually created using
PCR-ampliﬁed gene sequences with about 40 base pairs of
ﬂanking sequences that are homologous to the viral BAC
[63].
There are also alternatives to the exo-gam-beta system
forhomologousrecombination.Forexample,plasmid-based
systemscanalsobe usedto allowforcreationof recombinant
DNA via homologous recombination in E. coli [67]. There
are also tools for “markerless” genetic manipulation, includ-
ing technologies that allow for site-directed mutagenesis
























Figure 1: Construction of HCMVBAC. (a) HCMV genome and bacterial plasmid with BAC vector that has been linearized and transfected
into human ﬁbroblast cells. (b) BAC vector is inserted into HCMV genome by homologous recombination. The viral genome (now
containing the BAC vector) will naturally circularize during replication. (c) HCMV viral BACs are selected based upon expression of a
GFP cassette within the BAC vector. (d) Fluorescent plaques are isolated, and viral BAC DNA is extracted. (e) Viral BACs inserted into E.
coli cells via electroporation. Successful integration of the BAC vector into the viral genome can be conﬁrmed by (1) selecting colonies with
antibioticresistanceresultinginthechloramphenicol-selectable marker intheBACvector and(2)conﬁrmingtheBACgenome sequence has
not gained any undesired mutations by using restriction digest analysis to compare the BAC DNA to the original viral DNA. (f) If desired,
mutagenize the HCMV viral BAC (via site-directed mutagenesis or random transposon mutagenesis). Either way, viral BAC DNA must
be isolated via Maxiprep for transfection back into human cells. (g) Transfect BAC DNA into human ﬁbroblast cells in order to produce
infectious virus.
Table 3: Global studies of human herpesvirus gene function.









2003 [52] HCMV (Towne) 45 35 68 4
Yu et al. 2003
[50] HCMV (AD169) 41 27 88 0
Zhang et al.
2010 [53] VZV 44 8 18 0
Phenotypes are considered for growth in human ﬁbroblast cells for HCMV and human melanoma (MeWo) cells for VZV.
3.2. Site-Directed Mutagenesis Using a Positive Selectable
Marker. One popular method to manipulate herpesvirus
BACs is to use site-directed mutagenesis to insert foreign
elements into, delete DNA fragment from, or make point
mutation in the BAC genome [9, 10, 13, 69]. There are
multiple ways to carry out site-directed mutagenesis of a
viral BAC. For example, selectable markers are necessary
to conﬁrm the successful mutation of a viral BAC, and
selectable markers can take the form of a positive selectable
marker (such as an antibiotic resistance gene) or negative
selectable marker (such as a metabolic gene). The well-
established method of producing BAC mutants using an
antibiotic resistance gene as a positive selectable marker is
described in this paragraph and outlined in Figure 3(a).
Basically, the antibiotic marker is inserted at a region of
interest in the viral BAC using homologous recombination.
Only bacterial cells containing the desired mutation will be
able to grow in the presence of antibiotic. Selectable markers
will need to be carefully selected; for example, the mutation
site cannot contain the same antibiotic marker as the BAC
vector. A detailed overview of this method is shown in
Figure 3(a). The primary advantage to this system is that
it allows for precise modiﬁcation of the BAC viral genome.
Only deletion mutants can be produced using a single round
of positive selection, and these deletion mutants have the
potential to signiﬁcantly alter viral genomic structure and
aﬀect regulation of nearby genes. Therefore, the integrity of
t h ev i r a lg e n o m em u s tb ec o n ﬁ r m e db yc r e a t i n gar e s c u e
virus. Thus, the primary disadvantage to this system is that it
requires two rounds of selection and is very time consuming.
In order to conﬁrm that mutants produced via homol-
ogous recombination with an antibiotic marker show a
phenotype that can be directly attributed to the designed
mutation, a rescue virus containing the original genomic
sequence musts be created. This is typically achieved with
via mutagenesis with a second positive selectable marker
(although the newly developed “Gene Capture” method [30]
can also be used when the genomic region of interest is
too large to be ampliﬁed via PCR). A detailed description
of method for producing a rescue virus is provided in6 Journal of Biomedicine and Biotechnology
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Figure 2: Construction of VZVBAC. (a) Schematic diagram of a VZV pOka genome. The 125-kb genome, VZV, contains a unique long (UL)
and a unique short (US) segment. (b) Four cosmids containing overlapping VZV genomic segments are shown. A BAC vector was inserted
betweenORF60-61inaVZVcosmid,pvSpe23,byhomologousrecombination.TheBACvectorcarriesaGFPandaCM
R marker.(c)VZVBAC
construction. (A) the BAC-containing cosmid was cotransfected with the three complementary cosmids into MeWo cells; (B) homologous
recombination between these four cosmids forms a circular full-length VZV genome; (C) the recombinant virus replicated and produced
a green plaque; (D) the circular DNA was isolated from infected cells and (E) transformed into E. coli and selected for CMR colonies; (F)
the VZVBAC DNA was isolated from E. coli and veriﬁed by restriction digestion and partial sequencing; (G) infectivity and integrity of the
VZVBAC were tested by transfecting BAC DNA into MeWo cells and producing VZV virus.
Figure 3(b). Production of a rescue virus requires another
round of positive selection using a diﬀerent marker. This
time, the selectable marker sequence must be ﬂanked by
sequences that will allow later excision from the genome
(e.g., sequences ﬂanked by loxP sequences can be removed
using Cre). This method of BAC excision will work for
any foreign element, including the BAC vector. For this
reason, BAC sequence excision methods should be carefully
considered, depending upon the design of the BAC. For
example, it will become problematic if both the BAC
vector and gene-speciﬁc antibiotic marker contain the same
ﬂanking excision sequences (such as loxP) because this is
likely to cause the removal of a much larger sequence of
genomic DNA than originally intended. If the viral BAC has
not accumulated any undesired mutations, then the rescue
virus should behave exactly like a wild-type viral BAC. As
described in the ﬁnal section of this paper, mutagenesis
methods utilizing two rounds of positive selection can also
be applied to produce certain types of mutants (such as
frame-shift or premature stop-codon mutants) as well as
gene fusions (such as GFP-fusion or epitope-tagged genes)
[70–72].
3.3. Site-Directed Mutagenesis Using a Negative Selectable
Marker. Site-directed mutagenesis can be accomplished
using galK as a negative selectable marker. The disadvantage
of using antibiotic resistance genes as a selectable marker (as
described above) is that the ﬂanking homologous sequences
that contain LoxP or FRT might cause the loss of viral
DNA during the process of making viruses in mammalian
cells. Thus, the process of making rescue mutants using an
antibiotic marker is complex and can induce unintended
mutations. However, these problem can be avoided by
using a negative selectable marker (such as galK)[ 69].
The process of this method is outlined in Figure 3(c).
Brieﬂy, viral BAC DNA is inserted into E. coli SW102 by
electroporation. Unlike DY380 E. coli c e l l s( w h i c hl a c ka
functional galactose operon), SW102 has a galactose operon
from which only galK has been deleted. Thus, SW102 with
a copy of a functional galK inserted can grow when the
only provided carbon source is galactose. Therefore, gene
modiﬁcations can be made by amplifying galK using PCR
primers homologous to the BAC sequence at the genomic
locusofinterest andthenselecting bacterialcoloniesthatcan
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Figure 3: BAC mutagenesis techniques. (a) generation of a deletion mutant via homologous recombination. (1) Ampliﬁcation of the kanR
expression cassette by PCR using a primer pair adding 40-bp (or longer) homologies ﬂanking ORFX. (2) Viral BAC DNA is introduced into
DY380 by electroporation. (3) Homologous recombination between upstream and downstream homologies of Gene X replaces Gene X with
a selectable marker (the KanR cassette), creating the Gene X-deletion viral BAC. (4) The recombinants are selected based upon their ability
to grown on LB agar plates containing kanamycin. (5) The viral BAC DNA is isolated, and the deletion of Gene X is conﬁrmed by PCR
analysis. The integrity of the viral genome (after homologous recombination) is examined by restriction enzyme digestion. (6) Puriﬁed BAC
DNA is transfected into a human cell line. (7) Viral proteins are expressed, and a functional virus is created. B. Generation of Rescue Virus.
1. Gene X is ampliﬁed by PCR from the wild-type BAC DNA. (2) Gene X is cloned into a bacterial plasmid. (3) Gene X and a selectable
maker (zeocin) are ampliﬁed via PCR using a primer pair that adds at least 40bp of nucleotide sequence that is homologous to viral genomic
sequenceﬂankingGeneX.(4)ThePCRproductwastransformedviaelectroporationintoDY380,nowcarryingtheGeneXdeletionmutant.
(5) and (6) Gene X (with a zeocin marker) is inserted back into the BAC by homologous recombination (7) The ZeoR vector sequence is
removed (by cotransfecting a Cre recombinase-expressing plasmid with the prepared viral BAC DNA). Rescue virus DNA is ready to be
puriﬁed and transfected into human cells. (c) GalK-based Mutagenesis (1). Insert galK sequence ﬂanked by a sequence homologous to the
viral BAC sequence ﬂanking Gene X. (2) Gene X is replaced by the galK gene via homologous recombination. (3) Replace the galK gene
with PCR product containing desired mutation in Gene X (referred to as Gene Y). (4) Transfect viral BAC into mammalian cells to produce
infectious mutant virus. (d) Transposon Mediated Mutagenesis. (1) and (2) A temperature-sensitive plasmid donor containing transposon
(Tn) is inserted into E. coli cells already containing viral BAC that was inserted via electroporation). Once the donor plasmid is inside the
cell, the transposon will be inserted into the BAC genome. (3) An increase in temperature will remove the donor plasmid. The transposon
mutant is now ready to be puriﬁed and transfected into human cells. PCR primers pre-engineered into the transposon insertion site can be
used to sequence the insertion region of any transposon mutants with interesting phenotypes.
Once colonies containing the galK gene are selected, the
galK gene can be replaced with a PCR product that contains
a modiﬁed sequence for the gene of interest. The bacteria
harboring BAC DNA with the galK gene will not grow
in minimal medium containing 2-deoxy-galactose (DOG)
because the digestion of DOG produces toxic products.
Therefore, colonies containing the modiﬁed gene sequence
can be quickly selected due to negative selection of colonies
with galK, which makes this time-saving system also highly
eﬃcient.
The method for creating rescue viruses using the galK
system is identical to the procedure outlined above. In other
words, the modiﬁed gene sequence is again replaced by the
galK gene, which can then be replaced a PCR sequence for
the original, unmodiﬁed gene sequence. Transfection of viral
BAC into mammalian cells can produce an infectious rescue8 Journal of Biomedicine and Biotechnology
mutant virus. This method for producing rescue viruses is
much simpler than the method described for site-directed
mutagenesis, which utilizes a positive selectable marker that
requires the addition of a new foreign DNA for excision of
unwanted sequence. However, this method also has certain
disadvantages, such as the tendency for BACs to accrue
undesired mutants. Although we have described negative
selection using galK, there are also other negative selectable
m a r k e r ss u c ha sR p s L / N e o[ 73], SacB [74] ,a n dT o l C[ 75].
3.4. Random Transposon Mutagenesis of Viral BACs. Trans-
poson mutagenesis is another popular method for manip-
ulating herpesvirus BACs [10, 13]. Transposons are mobile
genetic elements that insert themselves into genomic DNA
at essentially random locations, although diﬀerent classes
of transposons can have preferences for certain insertion
site sequences. For example, random mutagenesis of viral
BACs can be accomplished using a donor plasmid (such as
a Tn1721-derived insertion from a modiﬁed TnMax plasmid
[42,43,76–78])witha transposon thathas a preferenceto be
inserted into plasmid (rather than genomic) DNA [10]. This
insertion preference is useful because transposon insertion
is a relatively rare event (each mutant should typically only
haveonemutationperviralBAC),sopreferentialtransposon
insertion into viral BACs will save a considerable amount
of time by preventing transposon insertion into the E. coli
genome.
The process of transposon mutagenesis is outlined in
Figure 3(d). Brieﬂy, a transposon donor plasmid is ﬁrst
transformed into E. coli cells containing viral BACs in
order to allow insertion of the transposon into the viral
BAC. If the donor transposon sequence is present on a
temperature-sensitive plasmid, then temperature-sensitive
transposon donors can be eliminated by a shift in incubation
temperature so that the donor plasmid can no longer
replicate. The transposon cannot further replicate without
the donor plasmid because the transposon needs speciﬁc
genes in order to replicate, which genes are provided by the
donor plasmid. For example, Tn1721 requires transposase
(e.g., tnpA) and resolvase (e.g., tnpR)g e n e si no r d e rt o
replicate itself [42]. Transposase cuts donor and genomic
DNA, inserting the transposon into the viral BAC (along
with the donor plasmid). Resolvase enables homologous
recombination between inverted repeats (ﬂanking the trans-
poson sequence), thus allowing removal of the donor
plasmidsequenceandreplicationofthetransposonsequence
(now present both in the donor plasmid and the viral BAC).
Ifthetransposonmutantshowsaninterestingphenotype
during the infection of human cells, then the location of
the transposon insertion must be determined. Transposons
can be engineered so that ﬂanking PCR primers that can
be used to easily sequence the region of insertion can be
inserted [42]. There are other slightly diﬀerent methods
for transposon mutagenesis [10]. The primary advantage
to transposon mutagenesis is the speed with which a large
number of mutations can be produced in a number of
diﬀerent BAC mutants. The disadvantages are: (1) it can
be diﬃcult to locate the insertion site without specially
engineered transposons that contain PCR primer binding
sites for insertion site sequencing, (2) it takes a long time to
mutate every ORF because some ORFs will be “hit” multiple
times while others will not hit at all, and (3) the results
garnered by this method may be unclear (e.g., insertion in
the middle of an ORF may produce a partial yet functional
protein).
4. Studiesof SpeciﬁcHerpesvirusBACs
One of the ﬁrst human herpesvirus BACs was produced
for the herpes simplex virus (HSV-1) [17–19]. There have
been a large number of studies focusing on mutations in
o n eo rt w oH S V - 1g e n e s[ 79–84]. For example, one highly
cited study demonstrated that HSV-1 gene ICP0 acts as
an E3 ubiquitin ligase that can target cellular proteins for
degradation [85]. Viral BAC technology made the genetic
manipulations in this experiment feasible. There are also
viral BACs for the other major strain of the herpes simplex
virus (HSV-2) [20, 86], and both of these strains have
beenusedforHSV-2mutagenesisstudies.Pseudorabiesvirus
(PrV) is an alpha-herpesvirus that serves as a general model
for herpesvirus pathogenesis, especially HSV-1. The PrV
BAC was among one of the ﬁrst nonhuman herpesvirus
BACs to be constructed [46], and several PrV BAC mutants
have been created and analyzed [71, 87–89].
Human cytomegalovirus (HCMV) is the largest human
herpesvirus;it encodesaround 165 ORFs(althoughtheexact
gene count varies over time) and grows slowly in culture
[90]. Thus, BAC technology has been especially important
for genetic studies of HCMV. The ﬁrst BAC for HCMV was
produced around the same time as the ﬁrst HSV-1 BAC [25].
In fact, eight strains of HCMV have been cloned into viral
BACs [26–29]. Each of these HCMV BAC strains is useful for
diﬀerent studies due to their similarity to “wild type” viruses
that cause clinical infections or ability to grow in speciﬁc cell
lines. For example, AD169, Towne, and TB40 are considered
the “clinical” BAC strains whereas Toledo, FIX, PH, and
TR are considered to be the “laboratory” BAC strains [28].
The eight HCMV BAC strains also vary in the number of
generations that the parental virus was grown in cell culture
prior to creation of a viral BAC, which is important because
thatmeansthatheBACswillvaryinsimilaritytotheoriginal
clinical strain of virus. The self-excising AD169 BAC is also
unique because it is the only HCMV BAC contains the entire
genome of a clinical HCMV strain without containing the
BACvector[50].LackoftheBACvectorisimportantbecause
all other strains have a disruption of multiple US genes due
to insertion of the BAC vector.
There have been a number of individual studies of
HCMV BAC mutants [27, 91–93], but HCMV is unique
in that multiple global analyses have also been performed.
Global mutagenesis studies have utilized both random
transposon mutagenesis [77, 94] and knockouts created
via homologous recombination [52]. However, all these
global deletion studies do provide global identiﬁcation
of essential and nonessential genes. For example, Hobom
et al. sequenced only the HCMV glycoproteins followingJournal of Biomedicine and Biotechnology 9
global transposon mutagenesis [77]. Nevertheless, this study
indicated that gB, gH, gL, and gM are essential for viral
replication, but gp48 and gO are not (although the deletion
of gO results in a severe growth defect). These ﬁndings are in
complete agreement with later global studies [52, 94]. Global
studies of herpesvirus gene function that were conduced
in order to identify essential and nonessential genes are
discussed in the next section.
There are also multiple animal models used to study
HCMV pathogenesis. For example, there are BAC mutants
for murine cytomegalovirus (MCMV [12, 51, 95–97]),
rhesus cytomegalovirus (RhCMV [47, 98, 99]), and guinea
pig cytomegalovirus (GPCMV [38, 100, 101]). There was
also a large scale transposon mutagenesis study for MCMV
[42, 43], which was the ﬁrst global mutagenesis study
conducted on any herpesvirus [42].
The ﬁrst BAC for Epstein-Barr Virus (EBV) was also
produced around the same time as the ﬁrst HSV-1 BAC [24],
and several diﬀerent EBV BAC mutants have been produced
for speciﬁc functional analyses over the past decade [102–
107]. For example, Anderton et al. studied the pathogenesis
of Burkett’s lymphoma using three EBV deletion mutants
(EBNA3A, EBNA3B, and EBNA3C) in order to determine
that EBNA3A and EBNA3C cooperate to repress Bim, a
tumor-suppressor gene [103]. EBV is one of two human
gamma-herpesviruses (KSHV is the other human gamma-
herpesvirus).Gamma-herpesvirusesareuniquebecausethey
are oncogenic. Therefore, there are a number of popular
animal models for gamma-herpesviruses that are used to
study how gamma-herpesviruses inﬂuence the development
of cancer. The two most common animal models of gamma-
herpesviruses are herpesvirus saimiri (HVS) and murine
gamma-herpesvirus 68 (MHV-68); BAC mutants have been
produced for both of these viruses [39, 44, 108, 109]. In fact,
there is a global mutagenesis study for MHV-68 [45].
Kaposi’s Sarcoma-Associated Herpesvirus (KSHV) is
an oncogenic gamma-herpesvirus, and several KSHV BAC
m u t a n t sh a v eb e e nc o n s t r u c t e da n da n a l y z e d[ 32, 33, 110–
115]. For example, Lukac et al. studied how transcrip-
tional activator ORF50 reactivates viral replication following
latency by utilizing BAC mutants with deletions in down-
stream genes as well as BAC mutants with tandem histidine
tags added to ORF50 [116]. In addition to the general
gamma-herpesvirus animal models described for EBV (HVS
and MHV-68), a handful of rhesus rhadinovirus (RRV)
BAC mutants have been used to study KSHV pathogenesis
[48, 117]. In fact, researchers have created a RRV BAC
mutant with an autoexcisable BAC vector by inserting the
vector into terminal repeat region of the viral genome and
taking advantage of endogenous TR-mediated homologous
recombination [117], and this technology may be able to
applied towards creating traceless human herpesvirus BACs.
Varicella zoster virus (VZV) is the causative agent of
chickenpox and shingles. Several studies have utilized VZV
BACstostudytheroleofspeciﬁcVZVgenes[21–23,59,118],
and there has also been a recent global mutagenesis study to
determine which VZV genes are essential for viral replication
[53]. (For more information about global analysis of gene
function in VZV, see the next section.) VZV is the smallest
human herpesvirus, and it replicates more quickly than
some of the larger herpesviruses [4]. These features helped
facilitate the creation of a luciferase reporter gene in a VZV
BAC, which was the ﬁrst BAC with a complete herpesvirus
genome to utilize a luciferase reporter to help study viral
replication in vivo [22, 59]. The use of luciferase markers to
study viral replication is also discussed in the “Methods for
BAC Construction” section of this paper, under the topic of
“BAC Visualization Markers.”
Human herpesvirus 6 (HHV-6) and human herpesvirus
7 (HHV-7) are beta-herpesviruses (similar to HCMV). An
HHV-6 viral BAC has been constructed and HHV-6 BAC
mutants produced to study HHV-6 pathogenesis [31, 119].
However, it should be noted that the HHV-6 BAC has
not been sequenced, and the HHV-6 BAC is not currently
independently infectious due to the size of the BAC vector
(although this functionality should be present in a future
viral BAC). No viral BAC has been constructed for HHV-7.
BAC mutants have also been used to study the her-
pesviruses that cause pathogenesis in animals. Examples
include bovine herpesvirus type 1 (BHV-1 [34, 120, 121]),
equine herpesvirus type 1 (EHV-1 [36, 122–124]), feline
herpesvirus (FHV-1 [37, 125, 126]), koi herpesvirus (KHV
[40, 127]), Marek’s disease virus (MDV [41, 128, 129]), and
turkey herpesvirus (HVT [49]). In fact, a global mutagenesis
study has been conducted on BHV-1 [35], and a transposon
mutation study has been conducted on EHV-1 [130].
5. Global Studiesof GeneFunctionUsing
Human HerpesvirusBACs
Global studies of herpesvirus gene function are useful
because they can provide lists of essential and nonessential
genes for future studies [52, 53, 77, 94]. For example, the
discovery of new essential genes may reveal an appealing
novel drug target. Global studies on multiple cell and tissue
types can also reveal tissue-tropic virulence factors [52, 53].
Genes that show severe growth defects in certain tissues may
be appealing targets for mutagenesis in order to create a
live attenuated vaccine vector. Findings from global human
herpesvirus studies are outlined in Table 3.
HCMV is unique in that it is the only human herpesvirus
to have multiple global deletion studies for genome-wide
gene annotation. There are some discrepancies between
the two HCMV global annotation studies, but at least
some of these diﬀerences may be the results of subtle
diﬀerences between the HCMV strains (one study utilized
the AD169 BAC [94]; whereas the other used the Towne BAC
[52]). Genome annotations ﬂuctuate over time, so global
mutagenesis studies carried out at diﬀerent time may include
slightly diﬀerent sets of genes (e.g., Dunn et al. [52]p r o v i d e
annotations for 152 genes whereas Yu et al. [94]p r o v i d e
annotations for 156 genes). Methods for deﬁning growth
defect cutoﬀs were also slightly diﬀerent, so this may also
help explain diﬀerences in the number of nonessential genes
and genes whose deletion causes a growth defect (referred
to as “augmenting genes” in Table 3). Overall, the number
of essential genes is similar for these two studies, and both10 Journal of Biomedicine and Biotechnology
studies have similar broad conclusions, such as the tendency
for essential and nonessential genes to cluster close to one
another on the genome. One notable diﬀerence is that Dunn
et al. [52] report four genes whose deletion causes enhanced
growth (referred to as “repressive genes” in Table 3)b u t
Yu et al. [94]d on o tr e p o r ta n ys u c hg e n e s .I n s t e a d ,a l l
the genes whose deletion mutants caused enhanced growth
are identiﬁed as nonessential in the latter study. Therefore,
deletion of these genes could have caused an increase in
growth rate in both studies. Nevertheless, the authors of the
latter study might have simply decided that these genes were
exhibiting wild-type growth, especially since it can be hard
to assess statistical signiﬁcance for these studies. In general,
it is important to remember that these global studies usually
examine phenotypes only in one or two cell types (or tissue
types, in the case of VZV), and one deletion could interfere
with the expression of neighboring genes. Of course, in-
depth analysis of viral mutants produced in these global
studies will require the mutants that are produced (in these
studies) to be examined in other cell and tissue types.
Aside from HCMV, VZV is the only other herpesvirus
to have annotations of essential and nonessential genes
provided from a study of genome-wide mutagenesis [53].
The global study of gene function in VZV is also unique
in that growth phenotypes were examined both in cultured
h u m a nM e W oc e l l sa n di ns k i no r g a nc u l t u r ew h e r e a s
HCMV global studies only examined phenotypes in cultured
ﬁbroblasts [52, 94]. This experimental design allowed for
the discovery of skin-tropic virulence factors, three of which
(ORF10, ORF14, and ORF47) were previously established
in the literature, and one of which (ORF7) was a novel
discovery presented in this study. In general, conducting
global mutagenesis studies in other herpesviruses is likely to
be very useful. For example, HCMV and VZV have a similar
number of essential genes (between 41 and 45), but HCMV
has twice as many genes as VZV. Conserved genes are slightly
more likely to be essential, but all of the essential genes
do not necessarily have high sequence similarity between
human herpesviruses [53]. Therefore, it would be interesting
to see whether all the human herpesviruses have a similar
number of conserved essential genes and determine if these
genes always share a common biological function (such as
enrichment with genes related to DNA replication).
6. Other HerpesvirusBAC Applications
In addition to the local and global mutagenesis studies
described in the previous section, BAC mutants can serve as
a vector for genomic elements that can facilitate the study
of herpesvirus pathogenesis [131–133]. Gene modiﬁcations
(frame-shift mutations, premature stop-codon mutants,
point mutations, etc.) can be created using homologous
recombination, which requires two basic steps. First, PCR
primers for sequences ﬂanking the gene of interest are
designed as well as primers that contain the mutated region
of the gene of interest. Regions of the gene before and
after the mutation are ampliﬁed via PCR. For the second
step, these two fragments are combined and ampliﬁed via
PCR reaction, using the primers ﬂanking the sequence for
the original gene. This mutated gene sequence can then be
inserted into the BAC using homologous recombination,
similar to the method by which BAC deletion mutants
are created. Larger modiﬁcations can be created using
similar methods. For example, it may be useful to insert
an epitope tag (e.g. V5) into a gene sequence for a gene
without an existing antibody [70, 94, 134]. Chimeric genes
recognized by epitope antibodies can facilitate biochemical
analysis for genes of unknown function. Likewise, a similar
method can be used to create green ﬂuorescent protein
(GFP) fusion mutants. This technology was ﬁrst developed
for use in a PrV BAC to study the US9 gene [71]. In
general, GFP-fusion mutants can be useful for studying the
expression and localization patterns of viral genes [135–
138]. Protein complementation assays (PCAs) can also be
used to test protein-protein interactions (and conservation
of gene function between herpesviruses) between two gene
fragments inserted into a BAC [139]. New technologies have
also allowed for the creation of conditional deletion mutants
that contain destabilizing domains that can be stabilized by
addition of addition of the synthetic ligand (called shield-1),
thus allowing for knockout studies of essential genes [72].
This technology can also be useful for vaccine development
because vaccine strains can be grown in vitro with addition
of shield-1 but the strain will be unable to replicate when
injected into patients due to the lack of shield-1.
Another exciting area of herpesvirus BAC research is the
potential development of novel vaccines. BAC-based vaccine
candidates have been developed for HCMV [100, 140], HSV-
1[ 141, 142], and VZV (H. Zhu, unpublished data). An
MCMV vaccine was also developed as a proof of concept
[95, 143], and a live-attenuated guinea pig cytomegalovirus
vaccine has been shown to be immunogenic [101]. Inoc-
ulation of RhCMV in rhesus macaques has shown that
secondary RhCMV infections require inhibition of MHC-
1 antigen presentation, and this ﬁnding may be helpful in
designing an eﬀective HCMV vaccine [144]. An EHV-1 BAC
has also been used as a vector to induce an immune response
to produce West Nile Virus antibodies [145], express bovine
diarrhea virus structural proteins [146], and immunize mice
against Venezuelan Equine Encephalitis Virus [147].
HSV-1 BACs are also employed in gene therapy treat-
ments [142]. HSV-1-based gene therapy vectors contain
the viral genes necessary for viral replication, but lack the
virulence factors necessary to cause a clinical infection.
For example, HSV-1-based gene therapy vectors have been
developed in the hopes that they will be eﬀective in treating
cancer [60, 148] and osteoporosis [149]. EBV BACs have
also been used as gene therapy vectors in some situations
[61, 150].
In conclusion, the amount of biomedical research uti-
lizing herpesvirus BACs has grown rapidly during the
past decade, resulting in invaluable knowledge about viral
pathogenesis, vaccine development, and gene therapy. Since
the construction of the ﬁrst herpesvirus BAC 12 years
ago, BACs have been generated for all major human
and animal herpesviruses, and this technology has greatly
facilitated genetic and functional studies of herpesvirusesJournal of Biomedicine and Biotechnology 11
because recombinant herpesviruses were previously diﬃcult
to produce due to their large size. Soon, we may have BACs
for all the human herpesviruses as well as novel global
mutational studies for several herpesvirus BACs. Global and
localstudiesofherpesviruspathogenesisshouldhelpidentify
new antiviral targets and produce more eﬀective and safe
vaccines. For example, additional mutagenesis studies may
be useful in revealing tissue tropism factors and/or novel
viral-host interactions. In short, future herpesvirus BAC
studies should help provide exciting new discoveries about
viral pathogenesis as well as therapeutics for both viral and
nonviral diseases.
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